KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Equity Ratio (2016 - 2025)

Inovio Pharmaceuticals' Equity Ratio history spans 16 years, with the latest figure at 0.42 for Q2 2025.

  • For Q2 2025, Equity Ratio fell 42.17% year-over-year to 0.42; the TTM value through Jun 2025 reached 0.42, down 42.17%, while the annual FY2024 figure was 0.61, 11.84% down from the prior year.
  • Equity Ratio for Q2 2025 was 0.42 at Inovio Pharmaceuticals, down from 0.59 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.89 in Q1 2021 and bottomed at 0.42 in Q2 2025.
  • The 5-year median for Equity Ratio is 0.72 (2023), against an average of 0.71.
  • The largest annual shift saw Equity Ratio surged 104.34% in 2021 before it crashed 42.17% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.81 in 2021, then fell by 20.83% to 0.64 in 2022, then increased by 7.59% to 0.69 in 2023, then dropped by 11.84% to 0.61 in 2024, then crashed by 30.91% to 0.42 in 2025.
  • Per Business Quant, the three most recent readings for INO's Equity Ratio are 0.42 (Q2 2025), 0.59 (Q1 2025), and 0.61 (Q4 2024).